Patents by Inventor Mallaiah Mittakanti

Mallaiah Mittakanti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Unsymmetrically linked bisnaphthalimides as antitumor agents
    Patent number: 5604095
    Abstract: The present invention provides novel bis-naphthalimides characterized by having a linker containing a heteroatom, their preparation, pharmaceutical compositions thereof, and various methods of using the bis-naphthalimides. Particularly preferred bis-naphthalimides have a linker of about 8-16 atoms where the heteroatom is oxygen, sulfur, sulfur oxide or sulfur dioxide. The bis-naphthalimides provided herein have exceptional DNA binding properties and demonstrate cytotoxicity in both in vitro and in vivo tumor models, in particular, against melanoma.
    Type: Grant
    Filed: July 22, 1994
    Date of Patent: February 18, 1997
    Assignee: Cancer Therapy & Research Center
    Inventors: Alexander L. Weis, Shih-Fong Chen, Peech S. Reedy, Mallaiah Mittakanti, Daniel L. Dexter
  • Diamine platinum naphthalimide complexes as antitumor agents
    Patent number: 5561042
    Abstract: The present invention provides novel bis-naphthalimides characterized by having a linker containing a heteroatom, their preparation, pharmaceutical compositions thereof, and various methods of using the bis-naphthalimides. Particularly preferred bis-naphthalimides have a linker of about 8-16 atoms where the heteroatom is oxygen, sulfur, sulfur oxide or sulfur dioxide. The bis-naphthalimides provided herein have exceptional DNA binding properties and demonstrate cytotoxicity in both in vitro and in vivo tumor models, in particular, against melanoma. Also provided a novel mono-naphthalimides linked to a DNA alkylating agent. These agents are shown to have conformational effects on double stranded DNA and to form covalent adducts after an extended incubation period.
    Type: Grant
    Filed: January 30, 1995
    Date of Patent: October 1, 1996
    Assignee: Cancer Therapy and Research Center
    Inventors: Alexander L. Weis, Shih-Fong Chen, Peech S. Reddy, Mallaiah Mittakanti, Daniel L. Dexter, Jan M. Woynarowski
  • Alkylcarbamoylborane cyclic dimers
    Patent number: 5196581
    Abstract: Alkylcarbamoylborane cyclic dimers are synthesized through reactions of alkylcarbamoylborane adducts of amines. The inventive dimers have utility as reactants in the direct synthesis of alkylcarbamoylborane adducts of primary and secondary amines. Alkylcarbamoylborane adducts of primary and secondary amines and certain of the inventive dimers have biological activity as anti-tumor, hypocholesteremic, and anti-inflammatory agents. The cyclic dimers of this invention have the formula [BHRC(O)NHR'].sub.2, examples of which include:[BH.sub.2 C(O)NHC.sub.2 H.sub.5 ].sub.2[BH.sub.2 C(O)NHCH.sub.3 ].sub.2[BH.sub.2 C(O)NHCH.sub.2 CH.sub.2 CH.sub.3 ].sub.2[BH.sub.2 C(O)NHCH.sub.2 CH.dbd.CH.sub.2 ].sub.2.[BH.sub.2 C(O)NHC(CH.sub.3 ].sub.2.[BH(CH(CH.sub.3)CH.sub.2 CH.sub.3)C(O)NHCH.sub.2 CH.sub.3 ].sub.2.
    Type: Grant
    Filed: May 1, 1991
    Date of Patent: March 23, 1993
    Assignee: Utah State University Foundation
    Inventors: Karen W. Morse, Mohammad-Reza M.-D. Charandabi, Debra A. Feakes, Mallaiah Mittakanti